De et al., 2024 - Google Patents
Why Perfluorocarbon nanoparticles encounter bottlenecks in clinical translation despite promising oxygen carriers?De et al., 2024
- Document ID
- 14706639877300970903
- Author
- De A
- Jee J
- Park Y
- Publication year
- Publication venue
- European Journal of Pharmaceutics and Biopharmaceutics
External Links
Snippet
Abstract Artificial Oxygen Carriers (AOCs) have emerged as ground-breaking biomedical solutions, showcasing tremendous potential for enhancing human health and saving lives. Perfluorocarbon (PFC)-based AOCs, in particular, have garnered significant interest among …
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 [O] 0 title abstract description 171
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparation Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparation Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0457—Semi-solid forms, ointments, gels, hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48776—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form forms of ingredients not provided for by groups A61K47/48784 - A61K47/48992, e.g. cells, cell fragments, viruses, ghosts, red blood cells, viral vectors having the pharmacologically or therapeutically active agent complexed or covalently linked to, or being themselves modified by complexation or covalent linkage by a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jägers et al. | Perfluorocarbon-based oxygen carriers: from physics to physiology | |
Li et al. | Recent advances of biomimetic nano-systems in the diagnosis and treatment of tumor | |
Lambert et al. | Pharmaceutical design and development of perfluorocarbon nanocolloids for oxygen delivery in regenerative medicine | |
US5403575A (en) | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them | |
Lowe | Fluorinated blood substitutes and oxygen carriers | |
Pape et al. | Alternatives to allogeneic blood transfusions | |
JPH03502693A (en) | Improved emulsions of highly fluorinated organic compounds | |
KR19990022355A (en) | Blood dilution facilitated by monitoring of oxygenation status | |
JP6807740B2 (en) | Blood substitute composition and its usage | |
Lowe | Synthetic oxygen transport fluids based on perfluorochemicals: applications in medicine and biology | |
CN101448485B (en) | Optimized fluorocarbon emulsions for blood substitutes and other therapeutic uses | |
Faithfull | Fluorocarbons: Current status and future applications | |
De et al. | Why Perfluorocarbon nanoparticles encounter bottlenecks in clinical translation despite promising oxygen carriers? | |
AU647372B2 (en) | Fluorocarbon emulsions having saturated phospholipid emulsifiers | |
Njoku et al. | Haemoglobin-based oxygen carriers: indications and future applications | |
US10137147B2 (en) | Reducing the proliferation of lung carcinoma cells (A549) by administration of a poly-oxygenated metal hydroxide | |
RU2259819C1 (en) | Emulsion of perfluoroorganic compounds of medicinal indication and method for its obtaining | |
Zhao et al. | Perfluorocarbon-based oxygen carriers: What is new in 2024? | |
Edwards et al. | Fluids of the future | |
Peng et al. | A superstable homogeneous lipiodol-nanoformulation to overcome the dilemma of interventional embolization chemotherapy | |
Lane | Perfluorochemical-based artificial oxygen carrying red cell substitutes | |
US8945611B2 (en) | Artificial oxygen carriers and use thereof | |
Zhang et al. | Cyclic RGD functionalized PLGA nanoparticles loaded with noncovalent complex of indocyanine green with urokinase for synergistic thrombolysis | |
US10137148B2 (en) | Reducing the proliferation of adenocarcinoma cells (CaCo-2) by administration of a poly-oxygenated metal hydroxide | |
Krafft | Perfluorocarbons and perfluorocarbon emulsions for pulmonary indications |